ketoprofen has been researched along with Pancreatic Neoplasms in 1 studies
Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.
ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, XL | 1 |
| Yang, YR | 1 |
| Mo, XF | 1 |
| Wei, JL | 1 |
| Zhang, XJ | 1 |
| You, QD | 1 |
1 other study available for ketoprofen and Pancreatic Neoplasms
| Article | Year |
|---|---|
Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1α pathway.
Topics: Animals; Antineoplastic Agents; Benzofurans; Cell Proliferation; Dose-Response Relationship, Drug; D | 2017 |
Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1α pathway.
Topics: Animals; Antineoplastic Agents; Benzofurans; Cell Proliferation; Dose-Response Relationship, Drug; D | 2017 |
Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1α pathway.
Topics: Animals; Antineoplastic Agents; Benzofurans; Cell Proliferation; Dose-Response Relationship, Drug; D | 2017 |
Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1α pathway.
Topics: Animals; Antineoplastic Agents; Benzofurans; Cell Proliferation; Dose-Response Relationship, Drug; D | 2017 |